Collagen inhibitors - Pipeline Insight, 2021

DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Hypertriglyceridemia Understanding
Hypertriglyceridemia: Overview
Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex — although additional quantitative or qualitative lipoprotein abnormalities can also be present. Patients can fluctuate between hypertriglyceridemic states: given an appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia. Elevated plasma triglyceride concentrations contribute to increased risk of cardiovascular disease, both directly and because such elevations “keep bad company” with associated risk factors such as obesity, metabolic syndrome, proinflammatory and prothrombotic biomarkers, and type 2 diabetes mellitus.

""Hypertriglyceridemia - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters
This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs
• Volanesorsen: Ionis Pharmaceuticals
Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.2 It is indicated to treat familial chylomicronemia, a genetic condition that prevents breakdown of triglycerides and chylomicrons. The drug is in phase 3 of clinical trials for the treatment of Hypertriglyceridaemia.

• AKCEA APOCIII LRx: Akcea Therapeutics
AKCEA-APOCIII-LRx is a ligand conjugated antisense (LICA) drug designed to reduce the production of apolipoprotein C-III, or apoC-III. ApoC-III is a protein produced in the liver that plays a central role in the regulation of serum triglycerides. Genetically reduced levels of apoC-III are correlated to lower levels of triglycerides and lower risk of cardiovascular disease whereas elevated levels of apoC-III correlate with high triglyceride levels that have been associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome. Akcea and Ionis are developing AKCEA-APOCIII-LRx to treat hypertriglyceridemia
Further product details are provided in the report……..

Hypertriglyceridemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hypertriglyceridemia
There are approx. 30+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include,.Ionis Pharmaceuticals

• Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights
• Hypertriglyceridemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypertriglyceridemia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Hypertriglyceridemia drugs?
• How many Hypertriglyceridemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypertriglyceridemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Ionis Pharmaceuticals
• Akcea Therapeutics
• Acasti Pharma
• Teva Pharmaceutical
• Matinas BioPharma
• Pfizer
• Mochida Pharmaceutical
• Liminal BioSciences
• NorthSea Therapeutics
• Madrigal Pharmaceuticals
• Arrowhead Pharmaceuticals
• Soleno Therapeutics
• Pronova BioPharma
• AstraZeneca
• Regeneron Pharmaceuticals
• Staten Biotechnology
• Afimmune

Key Products
• Volanesorsen
• AKCEA APOCIII LRx
• Omega-3 phospholipid
• BIO89 100
• Ethyl eicosapentaenoic acid
• Vupanorsen
• MND-2119
• Fezagepras
• SEFA 1024
• Resmetirom
• ARO-APOC3
• Diazoxide choline controlled release
• Omega-3 ethylester concentrate
• Omega-3 carboxylic acids
• Evinacumab
• STT-5058
• Epeleuton